Danaher's Beckman Coulter Diagnostics has received a CE mark for the Access MeMed BV assay, a host‑response test that helps clinicians differentiate between bacterial and viral infections in approximately 20 minutes.
Validated for use across Beckman Coulter's installed base of DxI 9000 and Access 2 immunoassay analyzers, the Access MeMed BV assay enables fast infection differentiation while leveraging laboratories' existing infrastructure and workflows. Beckman Coulter partnered with MeMed, a provider of advanced host‑response technologies, to bring the MeMed BV test into core laboratory settings.
The MeMed BV test has been shown to enhance clinical decision making, support clinicians in curbing unnecessary antibiotic use, and advance antimicrobial‑stewardship initiatives.
"By delivering rapid, highly reliable bacterial and viral differentiation on routine immunoassay systems, we're empowering care teams with the timely insights they need to guide appropriate treatment decisions, while optimizing laboratory efficiency using existing workflows," said Melissa Naiman, Medical & Scientific Affairs at Beckman Coulter Diagnostics.
"This collaboration with Beckman Coulter significantly accelerates our mission to make host-response testing available at scale," said MeMed CEO Eran Eden in a statement. "The MeMed BV test has repeatedly demonstrated its ability to improve clinical decision making, empower clinicians to reduce unnecessary antibiotic use, and support antimicrobial stewardship, backed by robust clinical and real-world evidence. Making the assay available on high-throughput laboratory analyzers allows healthcare systems to unlock those benefits for far more patients."
